MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells

被引:28
作者
Flis, Sylwia [1 ]
Gnyszka, Agnieszka [1 ]
Flis, Krzysztof [2 ]
Splawinski, Jacek [1 ]
机构
[1] Natl Med Inst, Dept Pharmacol, PL-00725 Warsaw, Poland
[2] Polish Acad Sci, Inst Biochem & Biophys, Lab Mutagenesis & DNA Repair, Warsaw, Poland
关键词
5-fluorouracil; MS275; SBHA; Colorectal cancer; Apoptosis; Synergism; HISTONE DEACETYLASE INHIBITOR; HUMAN LEUKEMIA-CELLS; SUBERIC BISHYDROXAMATE; APOPTOSIS; DIFFERENTIATION; THERAPY; ACETYLATION; EXPRESSION; MELANOMA; DEATH;
D O I
10.1016/j.ejphar.2009.10.033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Histone deacetylases (HDACs) activity determines the acetylation status of histons, and has the ability to regulate gene expression through chromatin remodelling. HDACs are a promising target for pharmacological inhibition, since it has been discovered that some genes are repressed by their inappropriate recruitment. To test this we have addressed the hypothesis that histone deacetylase inhibitors SBHA and MS275 potentiate inhibitory effects of classical anti-colorectal cancer cytostatic, 5-fluorouracil (5-FU), on survival of colorectal cancer (CRC) cells in vitro. We are reporting here that HDAC inhibitors show potent synergistic interaction with 5-FU. The observed synergism between HDAC inhibitors and 5-FU is most probably related to the augmented apoptotic signal allowed for significant (both biological and statistical) reduction of the cytotoxic doses. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:26 / 32
页数:7
相关论文
共 18 条
[1]   Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy [J].
Carew, Jennifer S. ;
Giles, Francis J. ;
Nawrocki, Steffan T. .
CANCER LETTERS, 2008, 269 (01) :7-17
[2]   ANALYSIS OF COMBINED DRUG EFFECTS - A NEW LOOK AT A VERY OLD PROBLEM [J].
CHOU, TC ;
TALALAY, P .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1983, 4 (11) :450-454
[3]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[4]   Acetylation of proteins as novel target for antitumor therapy: Review article [J].
Di Gennaro, E ;
Bruzzese, F ;
Caraglia, M ;
Abruzzese, A ;
Budillon, A .
AMINO ACIDS, 2004, 26 (04) :435-441
[5]   Isobolographic analysis of interactions: An update on applications and utility [J].
Gessner, PK .
TOXICOLOGY, 1995, 105 (2-3) :161-179
[6]   Dual targeting of epigenetic therapy in cancer [J].
Hellebrekers, Debby M. E. I. ;
Griffioen, Arjan W. ;
van Engeland, Manon .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2007, 1775 (01) :76-91
[7]  
*IARC, IARC TP53 MUT DAT
[8]  
Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928-4680(00)00053-5
[9]   Histone deacetylase inhibitors: Multifunctional anticancer agents [J].
Liu, Tao ;
Kuljaca, Selena ;
Tee, Andrew ;
Marshall, Glenn M. .
CANCER TREATMENT REVIEWS, 2006, 32 (03) :157-165
[10]   The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells [J].
Maggio, SC ;
Rosato, RR ;
Kramer, LB ;
Dai, Y ;
Rahmani, M ;
Paik, DS ;
Czarnik, AC ;
Payne, SG ;
Spiegel, S ;
Grant, S .
CANCER RESEARCH, 2004, 64 (07) :2590-2600